• Action Pharma A/S, of Arhus, Denmark, said that it has completed the last visit of its last patient in a Phase IIb study of AP214 for prevention of kidney injury in patients undergoing cardiac surgery. It will now proceed with compiling data from its eight clinical sites in the U.S. and Denmark and from its central laboratory. Reporting of top-line results is anticipated in September.

• Chelsea Therapeutics Ltd., of Charlotte, N.C., reached its target enrollment of 120 patients in a Phase II trial of its fibromyalgia candidate, droxidopa. It expects to report top-line results by the end of the year. An interim analysis carried out by an independent data monitoring committee last year showed efficacy in some treatment arms with no observed safety concerns.